• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

费城染色体阳性慢性髓性白血病急变期预后因素的研究。

A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia.

作者信息

Cervantes F, Rozman M, Rosell J, Urbano-Ispizua A, Montserrat E, Rozman C

机构信息

Postgraduate School of Haematology Farreras Valenti, University of Barcelona, Spain.

出版信息

Br J Haematol. 1990 Sep;76(1):27-32. doi: 10.1111/j.1365-2141.1990.tb07832.x.

DOI:10.1111/j.1365-2141.1990.tb07832.x
PMID:2223645
Abstract

In 80 patients with Ph-positive chronic myelogenous leukaemia the main clinical, haematological and cytogenetical data were recorded at diagnosis of blast crisis and evaluated for prognostic significance. At the time of the analysis 73 patients had died, with a median survival of 4-8 months from diagnosis of blast crisis for the whole series. When analysed as a time-dependent variable, the achievement of a favourable response to chemotherapy resulted in a longer patient's survival. On the other hand, the univariate analysis identified six pretreatment characteristics associated with a poorer prognosis: a longer chronic phase, presence of extramedullary blastic involvement, a platelet count below 200 x 10(9)/l, a less marked leucocytosis, a blood blast cell percentage higher than 10%, and presence of trisomy 8. The latter parameters were included in a multiple regression model together with the blast cell phenotype (lymphoid versus non-lymphoid), and only four of them (trisomy 8, duration of chronic phase, platelet count, and leucocyte count) retained their prognostic influence. When the therapeutical response was also included in the regression model, it proved to be the most important prognostic variable, followed by trisomy 8, length of chronic phase, extramedullary disease, and platelet count, whereas the leukocyte count lost its predictive value. Thus, in spite of the short overall survival of blast crisis patients, the identification of prognostic factors in such a haematological condition may be of interest, especially in the interpretation of new therapeutical approaches.

摘要

在80例Ph阳性慢性粒细胞白血病患者中,记录了原始细胞危象诊断时的主要临床、血液学和细胞遗传学数据,并评估其预后意义。分析时,73例患者已死亡,整个系列从原始细胞危象诊断起的中位生存期为4 - 8个月。当作为时间依赖性变量进行分析时,化疗取得良好反应可使患者生存期延长。另一方面,单因素分析确定了六个与预后较差相关的预处理特征:慢性期较长、存在髓外原始细胞浸润、血小板计数低于200×10⁹/L、白细胞增多不明显、血原始细胞百分比高于10%以及存在8号染色体三体。将后述参数与原始细胞表型(淋巴样与非淋巴样)一起纳入多元回归模型,其中只有四个参数(8号染色体三体、慢性期持续时间、血小板计数和白细胞计数)保留了其预后影响。当治疗反应也纳入回归模型时,它被证明是最重要的预后变量,其次是8号染色体三体、慢性期长度、髓外疾病和血小板计数,而白细胞计数失去了其预测价值。因此,尽管原始细胞危象患者的总体生存期较短,但在这种血液学疾病中识别预后因素可能是有意义的,特别是在解释新的治疗方法时。

相似文献

1
A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia.费城染色体阳性慢性髓性白血病急变期预后因素的研究。
Br J Haematol. 1990 Sep;76(1):27-32. doi: 10.1111/j.1365-2141.1990.tb07832.x.
2
Chronic myelogenous leukemia in blast crisis: retrospective analysis of prognostic factors in 90 patients.急变期慢性粒细胞白血病:90例患者预后因素的回顾性分析
Ann Hematol. 1996 Nov;73(5):225-30. doi: 10.1007/s002770050233.
3
[Blast crisis of chronic myeloid leukemia with positive Philadelphia chromosome: course and clinico-hematologic profile in 80 patients].
Med Clin (Barc). 1990 May 12;94(18):681-4.
4
[Cause of death, survival, and prognostic factors in a series of 98 patients with chronic myeloid leukemia].[98例慢性髓系白血病患者的死因、生存情况及预后因素]
Sangre (Barc). 1992 Oct;37(5):351-4.
5
Karyotypic findings as an independent prognostic marker in chronic myeloid leukaemia blast crisis.核型结果作为慢性髓性白血病急变期的独立预后标志物
Leuk Res. 1994 May;18(5):385-92. doi: 10.1016/0145-2126(94)90023-x.
6
Prognostic Factors, Response to Treatment, and Survival in Patients With Chronic Myeloid Leukemia in Blast Phase: A Single-Institution Survey.急变期慢性髓性白血病患者的预后因素、治疗反应及生存情况:一项单机构调查
Clin Lymphoma Myeloma Leuk. 2015 Dec;15(12):778-84. doi: 10.1016/j.clml.2015.09.007. Epub 2015 Sep 30.
7
Immunophenotypic characteristics of blast crisis of chronic myeloid leukaemia: correlations with clinico-biological features and survival.慢性髓系白血病急变期的免疫表型特征:与临床生物学特征及生存的相关性
Leukemia. 1993 Sep;7(9):1349-54.
8
Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.甲磺酸伊马替尼用于治疗费城染色体阳性慢性髓性白血病急变期。
Haematologica. 2003 Nov;88(11):1213-20.
9
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.酪氨酸激酶抑制剂时代慢性髓性白血病急变期患者的预后因素及生存结果:477例患者的队列研究
Cancer. 2017 Nov 15;123(22):4391-4402. doi: 10.1002/cncr.30864. Epub 2017 Jul 25.
10
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.BCR-ABL酪氨酸激酶特异性抑制剂在伴有费城染色体的慢性髓性白血病急变期和急性淋巴细胞白血病中的活性
N Engl J Med. 2001 Apr 5;344(14):1038-42. doi: 10.1056/NEJM200104053441402.

引用本文的文献

1
Impact of Genetic Polymorphisms and Biomarkers on the Effectiveness and Toxicity of Treatment of Chronic Myeloid Leukemia and Acute Myeloid Leukemia.基因多态性和生物标志物对慢性髓性白血病及急性髓性白血病治疗有效性和毒性的影响
J Pers Med. 2022 Sep 29;12(10):1607. doi: 10.3390/jpm12101607.
2
B-Lymphoid Blast Phase-Chronic Myeloid Leukemia: Current Therapeutics.B 淋巴母细胞白血病-慢性髓性白血病:当前的治疗方法。
Int J Mol Sci. 2022 Oct 5;23(19):11836. doi: 10.3390/ijms231911836.
3
South African study of blast phase chronic myeloid leukaemia: A poor prognostic outlook.
南非慢性髓性白血病急变期研究:预后不佳。
Afr J Lab Med. 2022 May 31;11(1):1578. doi: 10.4102/ajlm.v11i1.1578. eCollection 2022.
4
Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case.波纳替尼作为不适合异基因干细胞移植和/或传统化疗的急变期慢性髓性白血病患者的有效替代策略:1例报告
Case Rep Hematol. 2017;2017:6167345. doi: 10.1155/2017/6167345. Epub 2017 Aug 14.
5
Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.晚期慢性髓性白血病的疾病进展潜在机制及管理
Leuk Lymphoma. 2014 Jul;55(7):1451-62. doi: 10.3109/10428194.2013.845883. Epub 2013 Nov 12.
6
Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report.甲磺酸伊马替尼治疗慢性髓性白血病时发生中枢神经系统母细胞危象:一例报告
J Neurooncol. 2007 Aug;84(1):103-5. doi: 10.1007/s11060-007-9352-0. Epub 2007 Feb 23.
7
Bone marrow cytogenetic complete remission achieved by interferon-alpha plus cytarabine ocfosfate therapy in a patient with chronic myelogenous leukemia during extramedullary blast crisis.α干扰素联合阿糖胞苷磷酸酯治疗慢性粒细胞白血病髓外原始细胞危象患者实现骨髓细胞遗传学完全缓解
Int J Hematol. 2002 Feb;75(2):191-4. doi: 10.1007/BF02982027.
8
P53 tumor suppressor gene in chronic myelogenous leukemia: a sequential study.慢性粒细胞白血病中的P53肿瘤抑制基因:一项序贯研究。
Ann Hematol. 1995 Mar;70(3):129-33. doi: 10.1007/BF01682032.